<DOC>
	<DOCNO>NCT02993224</DOCNO>
	<brief_summary>Study evaluate patient preference deferasirox FCT deferasirox DT patient transfusion - dependent thalassemia non-transfusion -dependent thalassemia measure preference questionnaire Week 48</brief_summary>
	<brief_title>Open-label , Multicenter Study Assessing Preference Deferasirox Film-coated Tablet Compared Dispersible Tablet</brief_title>
	<detailed_description />
	<mesh_term>Thalassemia</mesh_term>
	<mesh_term>Deferasirox</mesh_term>
	<criteria>1 . Prior screening procedure perform , write informed consent/assent must provide . For pediatric patient , consent obtain parent ( ) legal patient 's representative . Investigators also obtain assent patient accord local , regional national guideline . 2 . Male female patient age ≥ 2 year 3 . Exjade naïve patient chelate naive patient treat chelators least 6 month , : a. Deferiprone/ DFP b. Deferoxamine /DFO c. Combination ( DFO + DFP ) 4 . Subject willing discontinue current iron chelation therapy least 7 day prior first day duration study 5 . Patients transfusiondependent thalassemia ( independent underlie condition ) transfusional iron overload show : serum ferritin level &gt; 1000 ng/ml screen available , LIC &gt; 3 mg Fe/g dw 6 month prior screen 6 . Patients nontransfusiondependent thalassemia iron overload show : serum ferritin level ≥ 800 ng/ml screen available , LIC ≥ 5 mg Fe/g dw 6 month prior screen 1 . Male female patient age &lt; 2 year 2 Written consent/assent patients/parents/legal representative obtain 3 Creatinine clearance contraindication limit locally approve prescribing information . 4 Serum creatinine level &gt; 1.5 x ULN ( upper limit normal ) 5 AST ( SGOT ) /ALT ( SGPT ) &gt; 5 x ULN , unless LIC confirm &lt; 10 mg Fe/dw within 6 month prior screen visit . 6 Significant proteinuria indicate urinary protein/creatinine ratio &gt; 0.5 mg/mg nonfirst void urine sample . 7 Patients significant impaired gastrointestinal ( GI ) function GI disease may significantly alter absorption oral deferasirox ( e.g . ulcerative disease , uncontrolled nausea , vomit , diarrhea , malabsorption syndrome , small bowel resection ) . 8 Clinical laboratory evidence active Hepatitis B Hepatitis C ( HBsAg absence HBsAb OR HCV Ab positive HCV RNA positive ) . 9 Patients psychiatric addictive disorder prevent give inform consent undergo treatment option patient unwilling unable comply protocol ( include use electronic device ePRO ) . 10 Patients know history HIV seropositivity ( Elisa Western blot ) . 11 History malignancy organ system , treat untreated , within past 5 year whether evidence local recurrence metastasis , exception localize basal cell carcinoma skin . 12 Patients participate another clinical trial receive investigational drug . 13 History hypersensitivity study drug excipients . 14 Significant medical condition interfere ability partake study ( e.g . systemic uncontrolled hypertension , unstable cardiac disease control standard medical therapy , systemic disease ( cardiovascular , renal , hepatic , etc. ) . 15 Women childbearing potential , defined woman physiologically capable become pregnant , unless use effective method contraception dose study treatment 16 Women consider postmenopausal child bear potential 12 month natural ( spontaneous ) amenorrhea appropriate clinical profile ( e.g . age appropriate , history vasomotor symptom ) surgical bilateral oophorectomy ( without hysterectomy ) tubal ligation least six week ago . In case oophorectomy alone , reproductive status woman confirm follow hormone level assessment consider child bear potential . 17 Sexually active male unless use condom intercourse take drug 28 day stop study medication father child period . A condom require use also vasectomize men order prevent delivery drug via seminal fluid .</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>thalassemia</keyword>
</DOC>